

ternary carbon signals at δ 73.1 and δ 42.5 facilitated their assignment to C-18, and C-20, respectively. Therefore, the location of the tertiary hydroxy group was determined to be at C-18. Concerning the location of the aldehyde group, COLOC experiment was also very helpful giving two, three and four bond correlations between the aldehyde proton and C-20, with C-19 (C-21), and C-18, respectively (Table 1). Considering ^{13}C chemical shift of C-29 methyl group at δ 27.0, the stereochemistry of aldehyde group was deduced to be β [18]. Since an interaction followed between C-18 OH and the aldehyde proton by a NOESY experiment C-18 OH would be also at β -position. Based on the above spectroscopic data, the structure of compound **1** was elucidated as 18-hydroxy-27-norolean-12,14-dien-30-al-28-oic acid.

The spectral data, particularly ^1H NMR spectrum of the second new compound **2** were similar to those of vergatic acid which was first obtained from *Salvia virgata* [19]. The HRMS gave a molecular ion peak at m/z 484.3211 corresponding to a molecular formula of $\text{C}_{30}\text{H}_{44}\text{O}_5$, having 9 degrees of unsaturation, which were accounted for by a pentacyclic ring system, one double bond, and three car-

bonyl groups. The IR spectrum supported the presence of three carbonyl bands observing at 1735, 1720 and 1690 cm^{-1} which indicated an isolated keto, aldehyde and acid carbonyls, respectively. In the ^1H NMR spectrum, six methyl singlets were observed at δ 0.77, 0.79, 0.93, 0.99, 1.08 and 1.25. The aldehyde proton appeared as a broadened singlet at δ 9.32. The presence of a Δ^{12} double bond at δ 5.31 ($J = 2.5\text{ Hz}$), and a C-3 proton signal bearing a hydroxyl group at δ 3.20 ($J = 5$ and 10 Hz), are characteristic for olean-type triterpenes. The presence of an isolated keto group in the structure was indicated by the IR spectrum with an absorption band at 1735 cm^{-1} , and this was supported by the MS. Considering the chemical shifts and multiplicities of H-3 and H-12, the plausible positions of the oxo group were C-1, C-6, C-7, C-14, C-15, C-19, C-21 or C-22. However, rings D and E, as well as ring C, were easily eliminated for the location of the oxo group following RDA fragment ions at m/z 222, and 204. Therefore, the remaining localities for the oxo group were only C-1, C-6 and C-7. The most useful information was obtained from the ^{13}C NMR spectrum, and COLOC experiment (Table 1), which exhibited three bond correla-

Table 1: NMR data of compounds **1** and **2** (CDCl_3)

	1 ^1H	^{13}C	COLOC	2 ^1H	^{13}C	COLOC
1 α	0.78 ddd	38.6	C-10, C-9, C-5	–	211.4	
1 β	1.56 m		C-10, C-5	–		
2 α	1.36 m	21.2	C-3, C-1, C-4	2.20 dd	44.1	C-3, C-1, C-10
2 β	1.58 m		C-3, C-1, C-4	3.08 dd		C-3, C-1
3 α	1.12 ddd	42.4	C-23, C-24, C-1	3.20 dd	78.6	C-2, C-1, C-4
3 β	1.34 m		C-23, C-24, C-2	–		C-2, C-1, C-24
4	–	34.2		–	39.3	
5 α	0.89 dd	53.1	C-6, C-7, C-23, C-24	1.68 m	54.0	C-4, C-6, C-7
6 α	1.60 m	21.1	C-5, C-8	1.60 m	17.8	
6 β	1.43 ddd		C-5, C-8	1.46 m		
7 α	1.36 m	36.1	C-5, C-26	1.43 m	32.5	C-5, C-6, C-8, C-26
7 β	2.12 m		C-26	2.15 m		
8	–	41.1		–	42.0	
9 α	1.56 m	49.1	C-8, C-10, C-11	1.52 m	39.1	
10	–	41.0		–	52.3	
11 α	1.92 m	25.6	C-10, C-9, C-12	1.95 m	25.3	C-9, C-12
11 β	2.12 m		C-9, C-12	1.93 m		C-13
12	5.40 t	130.5	C-11, C-9, C-13, C-18, C-14	5.31 t	123.0	C-9, C-11, C-13, C-14
13	–	147.3		–	143.2	
14	–	163.6		–	39.4	
15 α	6.60 s	146.5	C-13, C-14, C-16, C-17, C-28	1.02 m	25.5	C-14, C-16
15 β	–			1.87 m		
16 α	–	204.2		2.0 m	22.0	C-15, C-17, C-28
16 β	–			0.88 m		
17	–	55.2		–	46.6	
18 β	–	73.1		1.66 dd	42.5	
19 α	2.40 d	50.1	C-18, C-20, C-30	1.47 m	40.1	
19 β	2.52 d			1.35 m		
20	–	42.5		1.50 m	42.5	
21 α	1.44 m	28.6	C-20, C-29, C-30	1.40 m	28.7	
21 β	1.75 m			1.80 m		C-20, C-22, C-30
22 α	2.48 m	35.4	C-28, C-29, C-30	2.60 m	35.7	C-17, C-21, C-28
22 β	2.32 m		C-28, C-30, C-18	2.20 m		
23	1.01 s	27.3	C-24, C-5, C-3, C-4	0.93 s	28.5	C-24, C-4, C-5
24	1.19 s	16.1	C-23, C-4, C-5	0.79 s	16.0	C-23, C-4, C-5, C-3
25	1.13 s	16.5	C-9, C-5, C-1, C-4	0.99 s	15.0	C-9, C-10, C-1
26	0.82 s	27.3	C-9, C-14	0.77 s	17.5	C-9, C-8, C-14
27	–	–		1.08 s	25.7	C-13, C-14, C-15
28	–	183.5		–	183.1	
29	1.19 s	27.0	C-20, C-30, C-19, C-21	1.25 s	28.4	C-20, C-30
30	9.67 br s	191.1	C-20, C-29, C-19, C-21	9.32 br s	190.2	C-20, C-29

^1H NMR J (Hz) for compound **1**: 1 α ,1 β = 13; 1 α ,2 β = 13.5; 1 α ,2 α = 2.5; 3 α ,2 β = 12; 3 α ,2 α = 3.5; 5 α ,6 β = 12; 5 α ,6 α = 2.5; 6 α ,6 β = 14; 6 β ,7 α = 13; 11 α ,12 = 11 β ,12 = 3; 19 α ,19 β = 12, (18 β -OH at 4.82 br s), for compound **2**: 2 α ,3 α = 5; 2 α ,2 β = 13.5; 2 β , 3 α = 10; 11 α ,12 = 11 β ,12 = 2.5; 18,19 α = 11; 18,19 β = 3

Table 2: Evaluation of cytotoxic potential^a

Compd.	BC1	LU1	COL-2	KB	KB-V	P-388	LNCAp	ASK
1	>20	17.5	11.1	>20	>20	>5	15.7	–
2	>20	>20	>20	>20	>20	>5	>20	–
5 + 6	>20	17.7	>20	>20		>5	>20	–
9	10.4	7.5	9	>20	10.5	1.3	8.2	–
11 + 12	>20	>20	>20	>20	>20	>5	>20	–
13	>20	>20	>20	>20	>20	>5	>20	–
16 + 17	>20	>20	>20	>20	>20	>5	>20	–
Chloroform extract	>20	>20	>20	>20	>20	1.2	>20	–
Ellipticine (positive control)	0.2	0.02	0.3	0.04	0.3	0.1	0.8	–

^a Compounds were initially tested at a concentration of 20 µg/ml, and this was followed by dose-response studies, as required, to yield ED₅₀ values (µg/ml). With cultured ASK cells, tests were performed at a concentration of 20 µg/ml; colchicine was used as a positive control

tions between the keto carbonyl (211.4 ppm) and H-3 (δ 3.20), and two bond correlations between the keto carbonyl and CH₃-25, indicating the keto group should be at C-1. The location of the carboxyl group at C-17 followed from the MS which demonstrated a prominent fragment ion at m/z 440. Also, fragment ions at m/z 262, 218 and 189 arising from RDA cleavage were attributed to the location of acid and aldehyde groups to be in rings D or E. The correlation of the aldehyde carbon (190.2) with H-19, H-20 and H-21 in the COLOC experiment, was very indicative of the location of the aldehyde moiety to be at C-20. An interaction between the aldehyde proton and H-18β was clearly observed by a 2 D NOESY experiment [18, 20]. Thus, the structure of compound **2** was identified as 3β-hydroxy-1-oxo-olean-12-ene-30-al-28-oic acid. (vergatic acid-30-al = 1-oxo-dodecandral) [21].

Due to cytotoxic activity of betulinic acid and ursolic acid and their derivatives the compounds **1**, **2**, **5**, **6**, **9**, **11**, **12**, **13**, **16** and **17** isolated in sufficient amount and the chloroform extract were evaluated for cytotoxicity against a number of cell lines (see Table 2). While the chloroform extract was found to be highly active against P-388 (1.2 µg/ml), compound **1** showed a weak cytotoxic response against human colon cancer (11.1 µg/ml), hormone-dependent human prostate cancer (15.7 µg/ml), and human lung cancer (17.5 µg/ml). Among the tested compounds, 11-oxo-β-amyrin (**9**) showed a general cytotoxic response against all cell lines, except KB, and was particularly active against P-388 (1.3 µg/ml). None of the compounds gave a positive response with the ASK cell line, indicating a lack of antimetabolic potential.

3. Experimental

3.1. General procedures

The spectra were recorded with the following instruments. IR: Perkin-Elmer 980 in CHCl₃; NMR: Bruker AC-200 L, 200 MHz and 50.32 MHz for ¹H and ¹³CNMR respectively, and Bruker DPX 400, in CDCl₃; MS: ZabSpec high resolution mass spectrometer; CC: Silica gel 60 was used for column chromatography and Kieselgel 60F₂₅₄ (E. Merck) for prep TLC with precoated plates.

3.2. Plant material

The plant material of *Lavandula stoechas* ssp. *stoechas* was collected from Gebze in Turkey, April 1996. The plant was identified and a voucher specimen was deposited in the Herbarium of Faculty of Pharmacy, Ankara University (AEF 19855).

3.3. Extraction and isolation

The powdered roots of the plant (800 g) were extracted with chloroform to yield 16 g of material. The extract was fractionated on a silica gel column (5 cm × 70 cm) eluting with hexane, followed by gradients with increasing

amounts of chloroform, after 100% CHCl₃, elution was continued with increasing amounts of acetone, then methanol. Compound **1** was isolated during elution with CH₂Cl₂:CH₃OH (75:25) and compound **2** during elution with CH₂Cl₂:CH₃OH (98:2), and then purified by prep. TLC using solvent systems (CH₂Cl₂:acetone) (50:50) for **1** and (CH₂Cl₂:acetone) (95:5) for **2**, and obtained 23 mg and 18 mg, respectively. Among the known compounds, **16** and **17** were isolated from (hexane:CH₂Cl₂) (1:2) while **9** from 100% CH₂Cl₂. The other known compounds were isolated during the elution of CH₂Cl₂:CH₃OH in increasing polarities: Compounds **7**, **8**, and **10** from CH₂Cl₂:CH₃OH (99:1), **14** from CH₂Cl₂:CH₃OH (98:2) **3** from CH₂Cl₂:CH₃OH (97:3), **4** from (CH₂Cl₂:CH₃OH) (96:4), **11**, **12** and **15** in (25:75), **5**, **6** and **13** from (50:50). The all known compounds were identified based on spectral data (¹HNMR and EIMS) and melting points which were in agreement with literature values.

3.3.1. 18-Hydroxy-27-norolean-12,14-dien-30-al-28-oic acid (**1**)

[α]_D²⁵ = +47.2° (c = 0.05); IR ν_{max}^{CHCl₃} cm⁻¹: 3640 (OH), 1720 (CHO), 1685 and 2500 (sh) (COOH); 1660 (conjugated C=O), 1600 and 760 (unsaturation); ¹HNMR (200 MHz, CDCl₃) (see Table 1); EIMS (rel. int) at m/z: 468.3 [M]⁺ (59), 450.3 [M-H₂O]⁺ (33), 438.3 [M-COH]⁺ (19), 435.3 [450-CH₃]⁺ (24), 423.3 [M-COOH]⁺ (30), 422 (15), 407.3 [422-CH₃]⁺ (26), 277.2⁺ (19), 248.1 (47), 215.1 (36), 203.1 (56), 186.1 [215-CHO]⁺ (37), 146.1 (100), 133.1 (53), 119.1 (46), 107.1 (34), 95.1 (32), 81.1 (30), 69.1 (25). HRMS: 468.2890 for C₂₉H₄₀O₅ (calcd. 468.2875); ¹³CNMR: see Table 1.

3.3.2. 3β-Hydroxy-1-oxo-olean-12-ene-30-al-28-oic acid (vergatic acid-30-al = 1-oxo-dodecandral) (**2**)

[α]_D²⁵ = +27.4° (c = 0.04); IR ν_{max}^{CHCl₃} cm⁻¹: 3440 (OH), 3000, 2980 (CH), 1735 and 1720, 1690 (C=O), 1685 (2500 sh); ¹HNMR (200 MHz, CDCl₃) (see Table 1); EIMS (rel. int) at m/z: 484.4 [M]⁺ (14), 440 [M-CO₂]⁺ (5), 422.3 [M-CO₂]⁺ (15), 407.3 (19), 276.3 (2), 262.2 (8), 248.2 (30), 222.2 (21), 218.2 (42), 204.2 [222-H₂O]⁺ (100), 189.1 [218-CHO]⁺ (53), 175.1 (55), 133.1 (53), 119.1 (45), 107.1 (38), 95.1 (42), 81.1 (30), 69.1 (21). HRMS: 484.3211 C₃₀H₄₄O₅ (calcd. 484.3188); ¹³CNMR: see Table 1.

3.4. Evaluation of cytotoxic activity

The CHCl₃ extract and compounds **1**, **2**, **5**, **6**, **9**, **11**, **12**, **13**, **16** and **17** were evaluated against cultured KB (human epidermoid carcinoma), BC1 (human breast cancer), LU1 (human lung cancer), COL-2 (human colon cancer), KB-V (+VLB) (drug-resistant KB), P-388 (mouse leukemia), LNCAp (hormone-dependent human prostate cancer), and ASK (rat glioma) cell lines [22].

Acknowledgement: This study was supported by the Research Foundation (Project No: 1574/16002000) of the University of Istanbul.

References

- 1 Mill, R. R.: in: Davis, PH, (Ed.): Flora of Turkey and the East Aegean Islands, Vol. 7, p. 77 University Press: Edinburgh, 1982
- 2 Saeed, M: Hamdard Pharmacopoeia of Eastern Medicine, Hamdard National Foundation Pakistan 1970
- 3 Baytop, T: Medicinal and Toxic Plants of Turkey, Ismail Akgün Press: Istanbul, 1967
- 4 Papanov, G.; Bozov, P; Malakov, P: Phytochemistry **31**, 1424 (1992)
- 5 Bozov, P; Papanov, G.; Malakov, P; Tomova, K.: Travaux Scientifiques **28**, 69 (1990)
- 6 Papanov, G.; Malakov, P; Tomova, K.: Travaux Scientifiques **22**, 213 (1984)

- 7 Ulubelen, A.; Gören, N.: *Phytochemistry* **27**, 3966 (1988)
- 8 Ulubelen, A.; Olcay, Y.: *Fitoterapia* **60**, 475 (1989)
- 9 Spring, F. S.; Vickerstaff, T.: *J. Chem. Soc.* 249 (1937)
- 10 Ikuta, A.; Itokowa, H.: *J. Nat. Prod.* **52**, 623 (1989)
- 11 Robinson, F. P. Jr.; Martel, H.: *Phytochemistry* **9**, 907 (1970)
- 12 Öksüz, S.; Topçu, G.: *Phytochemistry* **26**, 3082 (1987)
- 13 Ikuta, A.; Kamiya, K.; Satake, T.; Saiki, Y.: *Phytochemistry* **38**, 1203 (1995)
- 14 Ulubelen, A.; Topçu, G.; Lotter, H.; Wagner, H.; Eriş, C.: *Phytochemistry* **36**, 13 (1994)
- 15 Tanaka, R.; Tabuse, M.; Matsunaga, S.: *Phytochemistry* **27**, 3563 (1988)
- 16 Ulubelen, A.; Sönmez, U.; Topçu, G.; Johansson C. B.: *Phytochemistry* **42**, 145 (1995)
- 17 Budzikiewicz, H.; Wilson, J. M.; Djerassi, C.: *J. Am. Chem. Soc.* **85**, 3668 (1963)
- 18 Kaneda, N.; Pezzuto, J. M.; Kinghorn, A. D.; Farnsworth, N. R.: *J. Nat. Prod.* **55**, 654 (1992)
- 19 Ulubelen, A.; Ayanoğlu, E.: *Phytochemistry* **15**, 309 (1976)
- 20 Begum, S.; Siddiqui, F.; Siddiqui, B. S.: *J. Nat. Prod.* **60**, 20 (1997)
- 21 Spengel, S. M.: *Phytochemistry* **43**, 179 (1996)
- 22 Likhitwitayawuid, K.; Angerhofer, C. K.; Ruangrunsi, N.; Cordell, G. A.; Pezzuto, J. M.: *J. Nat. Prod.* **56**, 30 (1993)

Received March 26, 2001

Accepted June 6, 2001

Prof. Dr. Gülaçtı Topçu
TUBITAK, Marmara Research Center
Materials and Chemical Technologies
Research Institute
P.O. Box 21
41470, Gebze-Kocaeli
Turkey
Gulacti.Topcu@posta.mam.gov.tr